Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRIFTER
2024-511870-65-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of allogeneic pooled fecal microbiota in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Change in HbA1c at 6 months. Started Jan 2024; status: completed.
02
Drugs
allogeneic pooled fecal microbiota
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-511870-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511870-65-00.